An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: Use of Botulinum toxin type A (BTX-A) for facial wrinkles is well-documented, but current methods of subjective evaluation by clinicians and patients fail to objectively quantify the magnitude and duration of facial muscle paralysis. OBJECTIVE: (a) Determine the locus of facial muscular tension; (b) Quantify and monitor muscular paralysis and subsequent return; (c) Continuously correlate the appearance of wrinkles and muscular tension using non-invasive digital image speckle correlation (DISC) to measure treatment efficacy; (d) Corroborate objective data with existing rating scales (subject global assessment and facial lines outcome-11). METHODS: Two sequential images of slight facial motion (frowning, raising eyebrows) are taken with a camera for n = 6 patients pre- and post-treatment at different time points up to 24 weeks. DISC processes the images to produce a vector map of muscular displacement to obtain spatially resolved information regarding facial tension. RESULTS: We observed maximum paralysis (≥70%) at 2 weeks, and the rate of recovery varied widely ranging from 2 to 5 months, with two patients continuing to exhibit reduced contraction at 24 weeks. Vector analysis of pre-treatment contraction correctly predicted injection site and illustrated lines of maximum tension. CONCLUSIONS: Digital image speckle correlation can precisely track the degree of contraction of different muscle groups following BTX-A injection. It can help predict injection site, quantify muscle paralysis, and monitor the recovery following BTX-A injection. Results were found to be reproducible across six patients.

Full Text

Duke Authors

Cited Authors

  • Bhatnagar, D; Conkling, N; Rafailovich, M; Phillips, BT; Bui, DT; Khan, SU; Dagum, AB

Published Date

  • August 2013

Published In

Volume / Issue

  • 19 / 3

Start / End Page

  • 220 - 229

PubMed ID

  • 23565582

Electronic International Standard Serial Number (EISSN)

  • 1600-0846

Digital Object Identifier (DOI)

  • 10.1111/srt.12010


  • eng

Conference Location

  • England